A Study of BGB-11417 in Participants With Myeloid Malignancies

Recruiting now · Phase 1/Phase 2

Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm

In brief

The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

Key facts

Study ID
NCT04771130
Run by
BeOne Medicines
People needed
260
Starts
2021-05-24
Expected to finish
2028-02-08
Last updated by the study team
2026-07-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.